Truist Financial Lowers Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target to $1,137.00

Regeneron Pharmaceuticals (NASDAQ:REGN - Free Report) had its price target trimmed by Truist Financial from $1,200.00 to $1,137.00 in a research note published on Wednesday, Benzinga reports. The firm currently has a buy rating on the biopharmaceutical company's stock.

REGN has been the subject of a number of other reports. Morgan Stanley reduced their price objective on shares of Regeneron Pharmaceuticals from $1,183.00 to $1,182.00 and set an "overweight" rating for the company in a research report on Thursday, July 11th. StockNews.com upgraded shares of Regeneron Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Wednesday, October 9th. Leerink Partnrs cut shares of Regeneron Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, September 24th. Royal Bank of Canada increased their target price on shares of Regeneron Pharmaceuticals from $1,252.00 to $1,260.00 and gave the company an "outperform" rating in a research report on Friday, October 4th. Finally, BMO Capital Markets reiterated an "outperform" rating and issued a $1,300.00 target price on shares of Regeneron Pharmaceuticals in a research report on Tuesday, September 24th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating, sixteen have issued a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $1,116.00.

Regeneron Pharmaceuticals Price Performance

NASDAQ:REGN traded down $8.57 during trading hours on Wednesday, reaching $1,007.96. 367,109 shares of the company were exchanged, compared to its average volume of 493,190. The company has a current ratio of 5.44, a quick ratio of 4.62 and a debt-to-equity ratio of 0.10. The stock's 50-day moving average is $1,115.89 and its 200-day moving average is $1,040.15. The firm has a market cap of $111.06 billion, a PE ratio of 29.82, a price-to-earnings-growth ratio of 3.45 and a beta of 0.12. Regeneron Pharmaceuticals has a twelve month low of $769.19 and a twelve month high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported $11.56 earnings per share for the quarter, topping analysts' consensus estimates of $8.93 by $2.63. The company had revenue of $3.55 billion during the quarter, compared to analysts' expectations of $3.38 billion. Regeneron Pharmaceuticals had a net margin of 32.04% and a return on equity of 16.80%. The firm's revenue for the quarter was up 12.3% on a year-over-year basis. During the same period in the prior year, the business posted $8.79 earnings per share. On average, sell-side analysts anticipate that Regeneron Pharmaceuticals will post 37.82 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, VP Jason Pitofsky sold 487 shares of the firm's stock in a transaction that occurred on Wednesday, August 7th. The shares were sold at an average price of $1,070.00, for a total value of $521,090.00. Following the completion of the transaction, the vice president now owns 4,204 shares of the company's stock, valued at approximately $4,498,280. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other news, CFO Christopher R. Fenimore sold 5,680 shares of the firm's stock in a transaction that occurred on Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the completion of the transaction, the chief financial officer now owns 15,305 shares of the company's stock, valued at approximately $18,447,575.65. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, VP Jason Pitofsky sold 487 shares of the firm's stock in a transaction that occurred on Wednesday, August 7th. The shares were sold at an average price of $1,070.00, for a total transaction of $521,090.00. Following the completion of the sale, the vice president now directly owns 4,204 shares in the company, valued at approximately $4,498,280. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. 7.48% of the stock is currently owned by insiders.

Institutional Trading of Regeneron Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in the company. Tamar Securities LLC raised its holdings in Regeneron Pharmaceuticals by 16.6% in the third quarter. Tamar Securities LLC now owns 15,492 shares of the biopharmaceutical company's stock valued at $16,286,000 after acquiring an additional 2,211 shares in the last quarter. Bfsg LLC raised its holdings in Regeneron Pharmaceuticals by 3,352.0% in the third quarter. Bfsg LLC now owns 863 shares of the biopharmaceutical company's stock valued at $907,000 after acquiring an additional 838 shares in the last quarter. Transform Wealth LLC raised its holdings in Regeneron Pharmaceuticals by 7.5% in the third quarter. Transform Wealth LLC now owns 9,729 shares of the biopharmaceutical company's stock valued at $10,228,000 after acquiring an additional 677 shares in the last quarter. Sumitomo Life Insurance Co. raised its holdings in Regeneron Pharmaceuticals by 81.7% in the third quarter. Sumitomo Life Insurance Co. now owns 3,174 shares of the biopharmaceutical company's stock valued at $3,337,000 after acquiring an additional 1,427 shares in the last quarter. Finally, Kapitalo Investimentos Ltda acquired a new stake in Regeneron Pharmaceuticals during the third quarter worth approximately $337,000. Institutional investors and hedge funds own 83.31% of the company's stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.